Advertisement

Breast Cancer Research and Treatment

, Volume 158, Issue 1, pp 79–90 | Cite as

A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer

  • Martha HickeyEmail author
  • Jennifer L. Marino
  • Sabine Braat
  • Swee Wong
Clinical trial

Abstract

Discomfort during sexual activity is common after breast cancer. Vaginal estrogens are effective but commonly avoided due to systemic absorption. Despite the large commercial market for vaginal lubricants, no randomized studies have compared products. We aimed to compare efficacy and acceptability of two major types of lubricant for discomfort during sexual activity in postmenopausal breast cancer patients. In a single-center, randomized, double-blind, AB/BA crossover design, sexually active postmenopausal breast cancer patients used each lubricant for 4 weeks. The primary patient-reported efficacy outcome was total discomfort related to sexual activity (Fallowfield Sexual Activity Questionnaire Discomfort subscale SAQ-D). Acceptability was measured by patient preference and reported intention to continue using the products. Of 38 women analyzed, over 90 % experienced clinically significant sexually related distress at baseline. Water- and silicone-based lubricants did not differ statistically in efficacy based on total sexual discomfort (difference 0.7, 95 % confidence interval (CI) 0–1.4, p = 0.06). In a post hoc analysis, pain/discomfort during penetration improved more during silicone-based lubricant use than during water-based lubricant use (odds ratio 5.4, 95 % CI 1.3–22.1, p = 0.02). All aspects of sexual discomfort measured with diaries were reported more commonly with water- than silicone-based lubricant. Almost twice as many women preferred silicone-based to water-based lubricant than the converse (n = 20, 65 %, vs. n = 11, 35 %). 88 % continued to experience clinically significant sexually related distress despite use of either lubricant. Total sexual discomfort was lower after use of silicone-based lubricant than water-based, but many women continue to experience sexually related distress.

Keywords

Dyspareunia Sexual activity Lubrication Quality of life Survivorship 

Notes

Acknowledgments

Our thanks to the participants in the study, to study coordinator Soula Krejany, to study nurses Lee Ann Mahoney, Kathrine Allardice, and Lorraine Thomason, to research pharmacists Lisa Wolke and Christine Gilmartin and to the MSAC Clinic and RWH Pharmacy staff.

Author’s Contribution

M Hickey and JL Marino designed the study. M Hickey recruited the participants and provided supervision and overview of findings. JL Marino constructed the database and contributed to the statistical analysis of the data. S Wong managed the randomization and lubricant allocation. S Braat contributed to the statistical analysis of the data. All authors contributed to the manuscript.

Compliance with ethical standards

Conflict of interest

The study was partially supported by an educational grant from pjur, Luxembourg, which included supply of both water- and silicone-based lubricants but not packaging for double blinding. The company had no input into the study design, data collection, analysis of findings, interpretation of results, or writing of this manuscript. The pjur group approved the submitted version of this manuscript.

Supplementary material

10549_2016_3865_MOESM1_ESM.docx (12 kb)
Supplementary material 1 (DOCX 12 kb)
10549_2016_3865_MOESM2_ESM.docx (19 kb)
Supplementary material 2 (DOCX 18 kb)

REFERENCES

  1. 1.
    (2011) Personal lubricants. In: Chain drug review, Racher Press, New YorkGoogle Scholar
  2. 2.
    Andelloux M (2011) Products for sexual lubrication: understanding and addressing options with your patients. Nurs Womens Health 15:253–257. doi: 10.1111/j.1751-486X.2011.01642.x CrossRefPubMedGoogle Scholar
  3. 3.
    Atkins L, Fallowfield LJ (2007) Fallowfield’s Sexual Activity Questionnaire in women with without and at risk of cancer. Menopause Int 13:103–109PubMedGoogle Scholar
  4. 4.
    Avis NE, Crawford S, Manuel J (2004) Quality of life among younger women with breast cancer. J Clin Oncol 23:3322–3330CrossRefGoogle Scholar
  5. 5.
    Begg C, Cho M, Eastwood S et al (1996) Improving the quality of reporting of randomized controlled trials: the consort statement. JAMA 276:637–639. doi: 10.1001/jama.1996.03540080059030 CrossRefPubMedGoogle Scholar
  6. 6.
    Bell RJ, Fradkin P, Schwarz M, Davis SR (2013) Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 20:15–21. doi: 10.1097/gme.0b013e3182610cab CrossRefPubMedGoogle Scholar
  7. 7.
    Berman LA, Berman JR, Werbin T, Chabra S, Goldstein I (2001) The use of the Female Intervention Efficacy Index (FIEI) as an immediate outcome measure of medical intervention to treat female sexual dysfunction. J Sex Marital Ther 27:427–433. doi: 10.1080/713846821 CrossRefPubMedGoogle Scholar
  8. 8.
    Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974–986PubMedGoogle Scholar
  9. 9.
    Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23:259–263CrossRefPubMedGoogle Scholar
  10. 10.
    Calvert M, Blazeby J, Altman DG et al (2013) Reporting of patient-reported outcomes in randomized trials: the consort pro extension. JAMA 309:814–822. doi: 10.1001/jama.2013.879 CrossRefPubMedGoogle Scholar
  11. 11.
    Cella D (1997) Manual for the Functional Assessment of Cancer Therapy (FACT) quality of life instrument (version 4). Evanston Northwestern Health Care, EvanstonGoogle Scholar
  12. 12.
    Cella D, Land SR, Chang CH, Day R, Costantino JP, Wolmark N, Ganz PA (2008) Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat 109:515–526. doi: 10.1007/s10549-007-9682-9 CrossRefPubMedGoogle Scholar
  13. 13.
    Committee on Practice B-G (2012) ACOG Practice Bulletin No. 126: management of gynecologic issues in women with breast cancer. Obstet Gynecol 119:666–682. doi: 10.1097/AOG.0b013e31824e12ce CrossRefGoogle Scholar
  14. 14.
    Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J (2002) The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 28:317–330CrossRefPubMedGoogle Scholar
  15. 15.
    Dezzutti CS, Brown ER, Moncla B, Russo J, Cost M, Wang L, Uranker K, Kunjara Na Ayudhya RP, Pryke K, Pickett J, Leblanc MA, Rohan LC (2012) Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One 7:e48328. doi: 10.1371/journal.pone.0048328 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Edwards D, Panay N (2016) Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 19:151–161. doi: 10.3109/13697137.2015.1124259 CrossRefPubMedGoogle Scholar
  17. 17.
    Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261–4271. doi: 10.1200/jco.2004.08.029 CrossRefPubMedGoogle Scholar
  18. 18.
    Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189–199CrossRefPubMedGoogle Scholar
  19. 19.
    Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168CrossRefPubMedGoogle Scholar
  20. 20.
    Gelfand MM, Wendman E (1994) Treating vaginal dryness in breast cancer patients: results of applying a polycarbophil moisturizing gel. J Women’s Health 3:429–434CrossRefGoogle Scholar
  21. 21.
    Goetsch M, Lim J, Caughey A (2014) Assessing pain descriptors and prior attempts at therapy in survivors of breast cancer who have dyspareunia. J Sex Med 11:223Google Scholar
  22. 22.
    Goetsch MF (2012) Unprovoked vestibular burning in late estrogen-deprived menopause: a case series. J Low Genit Tract Dis 16:442–446CrossRefPubMedGoogle Scholar
  23. 23.
    Goetsch MF, Lim JY, Caughey AB (2014) Locating pain in breast cancer survivors experiencing dyspareunia a randomized controlled trial. Obstet Gynecol 123:1231–1236. doi: 10.1097/Aog.0000000000000283 CrossRefPubMedGoogle Scholar
  24. 24.
    Goetsch MF, Lim JY, Caughey AB (2015) A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 33:3394–3400. doi: 10.1200/jco.2014.60.7366 CrossRefPubMedGoogle Scholar
  25. 25.
    Goetsch MF, Lim JY, Caughey AB (2014) A solution for dyspareunia in breast cancer survivors a randomized controlled study. Obstet Gynecol 123:1sCrossRefGoogle Scholar
  26. 26.
    Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128. doi: 10.1200/jco.2009.25.9655 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hummel SB, van Lankveld JJDM, Oldenburg HSA, Hahn DEE, Broomans E, Aaronson NK (2015) Internet-based cognitive behavioral therapy for sexual dysfunctions in women treated for breast cancer: design of a multicenter, randomized controlled trial. BMC Cancer 15:321. doi: 10.1186/s12885-015-1320-z CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Johnsen M (2013) New FDA regulations bring lubricant introductions. In: Drugstore news. Lebhar-Friedman Inc., New York, p 100Google Scholar
  29. 29.
    Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalife S (2012) Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. J Sex Med 9:2066–2076. doi: 10.1111/j.1743-6109.2012.02771.x CrossRefPubMedGoogle Scholar
  30. 30.
    Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalife S (2012) Challenging atrophied perspectives on postmenopausal dyspareunia: a systematic description and synthesis of clinical pain characteristics. J Sex Marital Ther 38:128–150. doi: 10.1080/0092623x.2011.569641 CrossRefPubMedGoogle Scholar
  31. 31.
    Kingsberg SA, Kellogg S, Krychman M (2009) Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal oestrogen therapy. Int J Women’s Health 1:105–111CrossRefGoogle Scholar
  32. 32.
    Klykken P, Servinski M, Thomas X (2009) Silicone film-forming technologies for health care applications. In: Dow Corning internal publication, Literature No. 52-1068A-01. Dow Corning Corporation, MidlandGoogle Scholar
  33. 33.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E, members of the VVAPRG (2016) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23:243–256. doi: 10.1097/GME.0000000000000571 CrossRefPubMedGoogle Scholar
  34. 34.
    Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L (1983) Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 249:2195–2198CrossRefPubMedGoogle Scholar
  35. 35.
    Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N (1997) Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15:969–973PubMedGoogle Scholar
  36. 36.
    Moher D, Schulz KF, Altman DG, Lepage L (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191–1194. doi: 10.1016/S0140-6736(00)04337-3 CrossRefPubMedGoogle Scholar
  37. 37.
    Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper E-M, Sperner-Unterweger B, Holzner B (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128:553–561. doi: 10.1007/s10549-011-1378-5 CrossRefPubMedGoogle Scholar
  38. 38.
    Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 63:834–840. doi: 10.1016/j.jclinepi.2010.02.005 CrossRefPubMedGoogle Scholar
  39. 39.
    Suckling J, Lethaby A, Kennedy R (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. doi:  10.1002/14651858.CD001500.pub2
  40. 40.
    Thirlaway K, Fallowfield L, Cuzick J (1996) The Sexual Activity Questionnaire: a measure of women’s sexual functioning. Qual Life Res 5:81–90CrossRefPubMedGoogle Scholar
  41. 41.
    Ussher JM, Perz J, Gilbert E, School of Psychology, University of Western Sydney, Sydney, Australia (2011) Sexual wellbeing and breast cancer in Australia: experiences of people with breast cancer and health professionals. Breast Cancer Network Australia (BCNA), MelbourneGoogle Scholar
  42. 42.
    Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF, Decker DA (2012) effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 8:144–148. doi: 10.1200/jop.2011.000352 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H (2011) Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 16:424–431CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    World Health Organization (2012) Use and procurement of additional lubricants for male and female condoms: WHO/UNFPA/FHI360 advisory note 2012. WHO/RHR, GenevaGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Martha Hickey
    • 1
    • 2
    Email author
  • Jennifer L. Marino
    • 1
    • 2
  • Sabine Braat
    • 3
  • Swee Wong
    • 2
  1. 1.Department of Obstetrics and GynaecologyThe University of MelbourneParkvilleAustralia
  2. 2.Royal Women’s HospitalParkvilleAustralia
  3. 3.Melbourne School of Population and Global Health and Melbourne Clinical and Translational Sciences Platform (MCATS)The University of MelbourneParkvilleAustralia

Personalised recommendations